Hello and welcome to the 2026 virtual annual meeting of Metagenomi Therapeutics. Stockholders may submit questions by following the instructions on the annual meeting interface. I would like to turn the meeting over to Jian Irish. Jian, you may begin. Good morning, everyone. My name is Jian Irish, I am the President and Chief Executive Officer of Metagenomi Therapeutics. The meeting is now called to order. I've asked a designate of Goodwin Procter LLP, our outside Legal Counsel, to record the minutes. It is a pleasure to welcome our stockholders to the annual meeting of Metagenomi Therapeutics. This meeting is being held in accordance with the company's bylaws and the Delaware law. First, we'll take care of the formal business at hand, which is described in our notice and the proxy statement, a copy of which was mailed on or about April 27, 2026, to all of our stockholders of record at the close of business on April 13, 2026. During this portion of the meeting, all discussion will be limited to the official business at hand. Before proceeding to the formal business, I would like to welcome the Directors of the company and the members of our Executive team who are with us today, as well as the representatives from PricewaterhouseCoopers, Metagenomi Therapeutics' audit firm, and the representatives from Goodwin Procter, our outside counsel. Now let's proceed to the formal business of the meeting, notice of which was sent to all stockholders of record as of the close of business on April 13, 2026. Stockholders of record on that date are entitled to vote at this meeting. A record of stockholders as of that date has been on file at the principal place of business of the company for the last 10 days immediately prior to the date of this meeting, and has been available for inspection by any stockholder during that period at any time during normal business hours. Rules of conduct for the meeting are available in the Meeting Materials section on the right side of the screen. Please note that only stockholders who have logged in using their 16-digit control number will be able to vote and ask questions at the meeting. To allow us to answer questions from as many stockholders as possible, w e will limit each stockholder to two questions. If you have any questions, I would encourage you to please submit them now so that they will be in the queue to be answered. If any stockholder wishes to address the Chairperson during the formal part of this meeting, please do so by submitting your question in writing through the virtual meeting platform via the Ask a Question text box. The Board of Directors has appointed Lindsay Lamanna to act as Inspector of Election for this annual meeting, and she will tabulate the results of the voting. The Inspector of Election has signed the oaths of her office, which will be filed with the minutes of this meeting. Ms. Lamanna, do we have a quorum present? Yes, Chairperson. Of the 37,647,057 shares of common stock entitled to vote at the meeting, at least 1/3 of the total number of outstanding shares entitled to vote is represented, either in- person or by proxy, and therefore, a quorum is present. I declare that a quorum is present. We may now proceed to transact the business for which this meeting has been called. Let me briefly describe the voting procedures. Voting will be by proxy and by using the voting link provided through the virtual meeting platform. If you have previously turned in your proxy and you do not intend to change your vote, it is not necessary that you complete another proxy or ballot. Your vote will be counted. If you are eligible to vote and have not submitted your proxy, or if you want to change your vote, you may do so by clicking on the link provided through the virtual meeting platform. In order to allow stockholders to vote through the virtual meeting platform at any time during this meeting, I now declare the polls open for voting. Our first item of business is the election of Directors. At this meeting, we will be voting on two nominees for Class II Director to each serve for a term of three years, all as set forth in the proxy statement. In accordance with the bylaws, your Directors have nominated Juergen Eckhardt and Eric Bjerkholt to be elected to serve as Class II Directors. The company's bylaws require that the stockholders provide advance notice to the company of a stockholder's intent to nominate persons as directors. No such notice was received. Accordingly, I declare the nominations for Directors closed. The Board of Directors unanimously recommends that stockholders vote in favor of this proposal. The second item of business is the ratification of the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for our fiscal year ending December 31st, 2026. The Audit Committee of the Board of Directors, which consists entirely of independent Directors, appointed PricewaterhouseCoopers as the company's independent registered public accounting firm to audit the company's financial statements for the fiscal year ending December 31st, 2026. The Board of Directors approved the selection of PricewaterhouseCoopers and has asked the stockholders to ratify this selection. Stockholder ratification is not required by the company's bylaws. The Board of Directors is submitting this to the stockholders for ratification as a matter of good corporate governance. If the stockholders do not approve the selection of PricewaterhouseCoopers as the company's independent registered public accounting firm, the Board of Directors and the Audit Committee will reconsider the appointment. Anyone who has not yet voted and desires to do so, please do so now through the virtual meeting platform. The polls for each matter to be voted on at this meeting are now closed. No additional ballots, proxies or votes, no changes or revocations will be accepted. Inspector of Election, please report on the results of the voting. With regard to Proposal One, a plurality of the shares present or represented and entitled to vote have been voted in favor of the election of the persons nominated. With regard to Proposal Two, a majority of the shares present or represented and entitled to vote has been voted in favor of the ratification of PricewaterhouseCoopers as the company's independent registered accounting firm for the fiscal year ending December 31st, 2026. Thank you, Ms. Lamanna. I declare that all of the proposals presented at the meeting have been ratified or approved by the stockholders. The final results of voting, including any ballots and proxies recorded during this meeting, wiill b e set forth in the report of the Inspector of Election and will be included in the minutes of the meeting. The final results will be also included in our report filed with the SEC. There being no other matters for consideration at this meeting, I hereby adjourn the formal business portion of the annual meeting. We will now start the Q&A portion of the meeting. No relevant questions have been submitted. There are no relevant questions, I would like to thank everyone for joining us today at Metagenomi Therapeutics 2026 Annual Meeting of Stockholders. Enjoy the rest of your day. Ladies and gentlemen, this concludes the meeting, and you may now disconnect.